Outlooks on Epstein-Barr virus associated gastric cancer.
Outlooks on Epstein-Barr virus associated gastric cancer.
复制标题
DOI:
10.1016/j.ctrv.2018.03.006
复制
发表时间:
2018-05
影响因子:
11.8
通讯作者:
Lenz HJ
中科院分区:
文献类型:
--
作者:
Naseem M;Barzi A;Brezden-Masley C;Puccini A;Berger MD;Tokunaga R;Battaglin F;Soni S;McSkane M;Zhang W;Lenz HJ
Epstein-Barr virus associated gastric cancer (EBVaGC) comprises approximately 10% of gastric carcinomas. Multiple factors contribute to tumorigenesis, including EBV driven hypermethylation of tumor suppressor genes, inflammatory changes in gastric mucosa, host immune evasion by EBV and changes in cell cycle pathways. The unique molecular characteristics of EBVaGC, such as programmed death ligand 1 (PD-L1) overexpression, highlight the potential for using EBV as a biomarker for response to immunotherapy. Few studies have reported benefit from immunotherapy in EBV positive cancers, and clinical trials investigating the impact of checkpoint inhibitors in EBVaGC are currently underway. This review provides the most recent updates on molecular pathophysiology, epidemiology, clinical features and treatment advances pertaining to EBVaGC.
登录
查看更多内容
影响因子:
8.8
作者:
Camargo, M. C.;Murphy, G.;Koriyama, C.;Pfeiffer, R. M.;Kim, W. H.;Herrera-Goepfert, R.;Corvalan, A. H.;Carrascal, E.;Abdirad, A.;Anwar, M.;Hao, Z.;Kattoor, J.;Yoshiwara-Wakabayashi, E.;Eizuru, Y.;Rabkin, C. S.;Akiba, S.
通讯作者:
Akiba, S.
影响因子:
5.7
作者:
Ando Y;Inada-Inoue M;Mitsuma A;Yoshino T;Ohtsu A;Suenaga N;Sato M;Kakizume T;Robson M;Quadt C;Doi T
通讯作者:
Doi T
影响因子:
2.5
作者:
Cho J;Kang MS;Kim KM
通讯作者:
Kim KM
影响因子:
3.7
作者:
Cárdenas-Mondragón MG;Carreón-Talavera R;Camorlinga-Ponce M;Gomez-Delgado A;Torres J;Fuentes-Pananá EM
通讯作者:
Fuentes-Pananá EM
影响因子:
6.4
作者:
Camargo, M. Constanza;Koriyama, Chihaya;Rabkin, Charles S.
通讯作者:
Rabkin, Charles S.